Personal stories

Expertise, innovation and insight are fueling the development of remote and AI-powered approaches to healthcare—potentially improving treatment decisions and evolving the way clinical trials are designed and managed.

Her natural curiosity, determination and fascination with science inspired Esi Lamousé, M.D., Ph.D., to pursue a career that’s helped bring innovative therapies for inflammatory bowel disease to patients in need around the world.

Through collaborations with Americares, Heart to Heart International and the American Red Cross, Johnson & Johnson, with support from the J&J Foundation is standing with those who care for communities when catastrophe occurs.

Across three days, a group of New Jersey high school students participated in a broad range of STEM-focused activities, workshops, speaker sessions and a site tour as part of Johnson & Johnson’s WiSTEM²D Camp global initiative.

What once seemed like an unattainable goal may soon be within our grasp. Learn how Johnson & Johnson is working toward its vision to create a world without cancer.

These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

Artificial intelligence is revolutionizing healthcare—from improving surgical training and procedures to equipping healthcare providers with insights and personalizing care for patients around the world. See how the company is harnessing its extraordinary power.

After decades of commitment to understanding this neurodegenerative disease, company scientists have developed innovative therapies and tools that can potentially slow its progression and ease the psychological toll on patients and caretakers. A cure is still elusive—but preventing the disease may be within reach.

Learn how Johnson & Johnson is working to better address the needs of the 7 in 10 people with depression whose treatments aren’t providing enough relief.